Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases in the United States. Its lead product candidate is VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults. The company also has VOQUEZNA Triple Pak and VOQUEZNA Dual Pak, which have completed Phase III trials for treating Helicobacter pylori infection. Additionally, Phathom is developing VOQUEZNA and vonoprazan for heartburn associated with non-erosive GERD and for eosinophilic esophagitis in adults and adolescents. The company operates solely in the U.S. market.

Phathom Pharmaceuticals is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol PHAT. Its trading currency is the US Dollar (USD), as the company is based in the United States. The NasdaqGS is a major U.S. stock exchange that lists many biotechnology and healthcare companies, providing liquidity and visibility for investors.

Phathom Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on researching, developing, and commercializing innovative therapies for gastrointestinal diseases. Biotechnology companies like Phathom typically engage in drug discovery and clinical trials, aiming to bring new treatments to market for unmet medical needs.

Phathom Pharmaceuticals is headquartered in Florham Park, New Jersey, United States. The company primarily serves the U.S. market, as indicated by its focus on developing and commercializing treatments for gastrointestinal diseases within the United States. Its operations are centered in the U.S., and it does not have disclosed international operations or subsidiaries in other countries.

Phathom Pharmaceuticals generates revenue by developing and commercializing treatments for gastrointestinal diseases. Its main product candidates include VOQUEZNA for erosive GERD and heartburn, and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak for Helicobacter pylori infection. The company also has pipeline candidates for non-erosive GERD and eosinophilic esophagitis. Revenue is expected to come from sales of these products once approved and launched. As a biopharmaceutical company, it may also enter into licensing or partnership agreements, though specific financial arrangements are not detailed in the provided data.